Efficacy and Safety of Rituximab in Central Nervous System Demyelinating Disorders

BACKGROUND: Rituximab, an anti-CD20 monoclonal antibody, has been used worldwide as an off-label therapy in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). OBJECTIVE: The aim of the present study was to evaluate the efficacy and safety of rituximab in centr...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Varsha A., Kamat, Saurabh N., Lalkaka, Jamshed A., Singhal, Bhim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680882/
https://www.ncbi.nlm.nih.gov/pubmed/35002132
http://dx.doi.org/10.4103/aian.AIAN_167_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680882/
https://www.ncbi.nlm.nih.gov/pubmed/35002132
http://dx.doi.org/10.4103/aian.AIAN_167_21

Ejemplares similares